Cellectar Biosciences, Inc. (CLRB) Balance Sheet
CLRB balance sheet, 2025
December 31, 2025 · U.S. dollars$15.0M assets = $5.1M liabilities + $9.9M equity
Both columns are drawn to the same scale: what CLRB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CLRB financial health
Descriptive bands, not a rating. Fiscal 2025.
CLRB balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $15.3M2016 | $15.0M2025 | −0.3%/yr | |
| Total liabilities | $1.8M2016 | $5.1M2025 | +12.3%/yr | |
| Shareholders’ equity | $13.5M2016 | $9.9M2025 | −3.4%/yr | |
| Cash & short-term investments | $11.4M2016 | $13.2M2025 | +1.6%/yr | |
| Total debt | $94,5672016 | $409,5862025 | +17.7%/yr | |
| Net cash (debt) | $11.4M2016 | $12.8M2025 | +$1.4M | |
| Working capital | $10.6M2016 | $9.3M2025 | −$1.3M | |
| Current ratio | 7.472016 | 2.962025 | −4.51 | |
| Debt / equity | 0.012016 | 0.042025 | +0.03 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CLRB assets
CLRB liabilities and equity
CLRB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CLRB balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M | $57.2M | $10.6M | $13.3M | $10.0M | $11.4M |
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M | $57.2M | $10.6M | $13.3M | $10.0M | $11.4M |
| Short-term investments | — | — | — | — | — | — | — | $55,000 | $55,000 | $55,000 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $842,432 | $961,665 | $888,225 | $663,243 | $867,485 | $774,432 | $770,951 | $696,218 | $467,173 | $748,569 |
| Total current assets | $14.0M | $24.3M | $10.5M | $20.5M | $36.6M | $57.9M | $11.4M | $14.0M | $10.5M | $12.2M |
| Property, plant & equipment (net) | $910,076 | $1.2M | $1.6M | $978,975 | $549,135 | $638,347 | $783,924 | $543,339 | $244,713 | $1.4M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.4M | $3.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $75,000 | $75,000 | $540,823 | $0 | $0 |
| Other non-current assets | $29,780 | $29,780 | $29,780 | $81,214 | $81,214 | $6,214 | $6,214 | $18,086 | $0 | $0 |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M | $58.7M | $12.3M | $15.1M | $12.9M | $15.3M |
| Liabilities | ||||||||||
| Accounts payable | $1.4M | $4.1M | $5.6M | $2.6M | $1.4M | $1.4M | $1.3M | $1.5M | $1.9M | $1.4M |
| Short-term debt | $100,189 | $84,417 | $58,979 | $50,847 | $135,449 | $119,904 | $105,885 | $2,213 | $3,036 | $89,318 |
| Deferred revenue | — | — | — | — | $2.4M | $2.0M | $1.4M | $965,090 | −$1.9M | −$1.4M |
| Total current liabilities | $4.7M | $9.4M | $25.4M | $11.5M | $4.0M | $3.6M | $2.8M | $1.6M | $2.1M | $1.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,213 | $5,249 |
| Lease obligations | $409,586 | $494,003 | $552,982 | $603,828 | $301,741 | $421,644 | $527,529 | $2,213 | $5,249 | $7,976 |
| Other long-term liabilities | $309,397 | $1.8M | $494,003 | $552,981 | $166,292 | $301,740 | $421,644 | $171,000 | $0 | $146,583 |
| Total liabilities | $5.1M | $11.2M | $25.9M | $12.1M | $4.2M | $3.9M | $3.2M | $1.8M | $2.1M | $1.8M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $42 | $461 | $207 | $94 | $611 | $454 | $94 | $47 | $167 | $104 |
| Retained earnings (deficit) | −$269.1M | −$247.3M | −$202.8M | −$160.0M | −$150.9M | −$126.8M | −$111.7M | −$97.6M | −$84.3M | −$70.8M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | — | — | −$1.4M | — | — | $0 | −$309,405 | −$181,192 | −$5.8M | −$4.3M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $9.9M | $14.3M | −$13.8M | $9.5M | $33.0M | $54.8M | $9.1M | $13.3M | $10.8M | $13.5M |
| Key figures | ||||||||||
| Total debt | $409,586 | $494,003 | $552,982 | $603,828 | $301,741 | $421,644 | $527,529 | $2,213 | $5,249 | $94,567 |
| Net cash (debt) | $12.8M | $22.8M | $9.0M | $19.3M | $35.4M | $56.7M | $10.1M | $13.3M | $10.0M | $11.4M |
| Working capital | $9.3M | $14.9M | −$14.9M | $9.0M | $32.6M | $54.4M | $8.6M | $12.3M | $8.4M | $10.6M |
| Tangible book value | $9.9M | $14.3M | −$13.8M | $9.5M | $33.0M | $54.8M | $9.1M | $13.3M | $7.4M | $10.2M |
| Book value per share | $3.80 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 2.6M | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 | 16.26 | 4.11 | 8.60 | 4.95 | 7.47 |
| Quick ratio | 2.78 | 2.48 | 0.38 | 1.73 | 8.95 | 16.04 | 3.83 | 8.17 | 4.73 | 7.01 |
| Debt / equity | 0.04 | 0.03 | — | 0.06 | 0.01 | 0.01 | 0.06 | 0.00 | 0.00 | 0.01 |
| Equity / assets | 66.2% | 56.1% | −114.1% | 44.2% | 88.8% | 93.4% | 73.9% | 88.1% | 83.6% | 88.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $34.0M | $8.3M | $13.2M | $12.6M | $11.0M | $13.9M | $23.3M | $34.3M | $25.9M | $40.0M | $9.6M | $19.0M |
| Cash & equivalents | $34.0M | $8.3M | $13.2M | $12.6M | $11.0M | $13.9M | $23.3M | $34.3M | $25.9M | $40.0M | $9.6M | $19.0M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $883,659 | $920,038 | $842,432 | $1.1M | $1.6M | $987,495 | $961,665 | $1.6M | $2.0M | $1.3M | $888,225 | $1.1M |
| Total current assets | $34.9M | $9.3M | $14.0M | $13.6M | $12.6M | $14.9M | $24.3M | $35.9M | $27.9M | $41.4M | $10.5M | $20.1M |
| Property, plant & equipment (net) | $1.7M | $1.8M | $910,076 | $976,112 | $1.0M | $1.1M | $1.2M | $1.4M | $1.4M | $1.5M | $1.6M | $1.4M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $23,566 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 | $29,780 |
| Total assets | $36.6M | $11.1M | $15.0M | $14.6M | $13.7M | $16.0M | $25.5M | $37.3M | $29.4M | $42.9M | $12.1M | $21.6M |
| Liabilities | ||||||||||||
| Accounts payable | $5.2M | $4.7M | $1.4M | $4.0M | $4.7M | $3.9M | $4.1M | $8.3M | — | $7.4M | $9.2M | $7.8M |
| Short-term debt | $2,030 | — | $100,189 | $96,034 | $92,022 | $88,146 | $84,417 | $80,821 | — | $73,994 | $58,979 | $56,263 |
| Deferred revenue | — | — | — | — | — | — | — | −$6.5M | — | — | — | −$7.8M |
| Total current liabilities | $5.2M | $4.9M | $4.7M | $4.9M | $5.9M | $6.0M | $9.4M | $20.3M | $15.2M | $28.6M | $25.4M | $16.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.5M | $1.5M | $409,586 | $431,929 | $453,509 | $474,349 | $494,003 | $512,750 | $530,856 | $548,343 | $552,982 | $569,013 |
| Other long-term liabilities | $1.5M | $1.5M | $309,397 | $335,895 | $361,487 | $1.8M | $1.8M | $1.8M | $1.8M | $474,349 | $494,003 | $18.4M |
| Total liabilities | $6.8M | $6.4M | $5.1M | $5.2M | $6.2M | $7.8M | $11.2M | $22.1M | $17.0M | $29.0M | $25.9M | $34.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $83 | $42 | $42 | $32 | $18 | $461 | $461 | $406 | — | $332 | $207 | $99 |
| Retained earnings (deficit) | −$281.7M | −$274.8M | −$269.1M | −$263.8M | −$259.4M | −$253.9M | −$247.3M | −$245.0M | −$230.3M | −$229.4M | −$202.8M | −$210.0M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | −$331 | — | −$331 | −$207 | −$17.9M |
| Total shareholders' equity | $29.9M | $4.7M | $9.9M | $9.4M | $7.5M | $8.3M | $14.3M | $15.2M | $12.4M | $13.9M | −$13.8M | −$13.4M |
| Key figures | ||||||||||||
| Total debt | $1.5M | $1.5M | $409,586 | $431,929 | $453,509 | $474,349 | $494,003 | $512,750 | — | $548,343 | $552,982 | $569,013 |
| Net cash (debt) | $32.5M | $6.8M | $12.8M | $12.1M | $10.6M | $13.4M | $22.8M | $33.8M | — | $39.5M | $9.0M | $18.4M |
| Working capital | $29.6M | $4.4M | $9.3M | $8.7M | $6.8M | $8.9M | $14.9M | $15.6M | $12.7M | $12.8M | −$14.9M | $3.6M |
| Tangible book value | $29.9M | $4.7M | $9.9M | $9.4M | $7.5M | $8.3M | $14.3M | $15.2M | $12.4M | $13.9M | −$13.8M | −$13.4M |
| Book value per share | $2.44 | $1.11 | $2.34 | $2.97 | — | — | — | — | — | — | — | — |
| Shares outstanding | 12.2M | 4.2M | 4.2M | 3.2M | — | — | — | — | — | — | — | — |
| Current ratio | 6.66 | 1.90 | 2.96 | 2.77 | 2.15 | 2.47 | 2.58 | 1.77 | 1.84 | 1.45 | 0.41 | 1.22 |
| Quick ratio | 6.49 | 1.71 | 2.78 | 2.56 | 1.88 | 2.31 | 2.48 | 1.69 | 1.71 | 1.40 | 0.38 | 1.15 |
| Debt / equity | 0.05 | 0.32 | 0.04 | 0.05 | 0.06 | 0.06 | 0.03 | 0.03 | — | 0.04 | — | — |
| Equity / assets | 81.5% | 42.4% | 66.2% | 64.1% | 54.5% | 51.4% | 56.1% | 40.7% | 42.1% | 32.4% | −114.1% | −62.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 4, 2026); data from EODHD.
CLRB financial position
At the end of fiscal 2025 (December 31, 2025), Cellectar Biosciences had total assets of $15.0 million (down 41.2% from a year earlier), total liabilities of $5.1 million and shareholders' equity of $9.9 million. It held $13.2 million in cash and short-term investments against $0.4 million of debt, a net cash position of $12.8 million. Its current ratio was 2.96. In the latest quarter (ended June 30, 2026) total assets were $36.6 million and equity $29.9 million.
Related: CLRB income statement, CLRB cash flow statement, CLRB key metrics. See the CLRB stock overview for the latest quote and news.
CLRB balance sheet FAQ
What are Cellectar Biosciences's total assets?
Cellectar Biosciences reported total assets of $15.0 million at the end of fiscal 2025 (December 31, 2025), compared with $25.5 million a year earlier.
How much debt does Cellectar Biosciences have?
Cellectar Biosciences had $0.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.04.
How much cash does Cellectar Biosciences have?
Cellectar Biosciences held $13.2 million in cash and short-term investments at the end of fiscal 2025; with $0.4 million of debt that is net cash of $12.8 million.
What is Cellectar Biosciences's book value?
Cellectar Biosciences's shareholders' equity (book value) was $9.9 million at the end of fiscal 2025, or $3.80 per share.
What is Cellectar Biosciences's current ratio?
Cellectar Biosciences had current assets of $14.0 million and current liabilities of $4.7 million, a current ratio of 2.96 (it can cover its short-term obligations).